CD22/CD19 CAR-T cell immunotherapy
Sponsors
Daihong Liu, Liping Dou
Conditions
Lymphoma
Phase 2
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
Active, not recruitingNCT07094477
Start: 2025-04-01End: 2027-03-31Target: 50Updated: 2025-07-30
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
RecruitingNCT07587840
Start: 2026-01-01End: 2028-01-01Target: 20Updated: 2026-05-14
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
RecruitingNCT07779018
Start: 2026-04-01End: 2028-03-01Target: 30Updated: 2026-08-21